GI-Challenge Study for Gastroparesis Patients and Healthy Controls
NCT ID: NCT03896126
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
43 participants
OBSERVATIONAL
2019-01-01
2025-08-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vagal Nerve Stimulation for Gastroparesis
NCT03120325
Nutritional Drink in Gastroparesis
NCT03500354
Study to Intervene With Nutrition for Gastroparesis
NCT03987672
Intestinal Permeability and Gastroparesis
NCT04894656
Gastroparesis Registry 3
NCT03680859
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Current technology only allows for measurement of vagal nerve activity that regulates the heart and diagnostic tests focus specifically on cardiac vagal activity. Measuring vagal nerve activity as it pertains to the gastrointestinal system is an unmet medical need. Its importance will continue to grow since vagal nerve stimulation is being used increasingly in a myriad of different diseases, and currently there is no way of knowing if patients are getting too little or too much stimulation.
In this study, the gastrointestinal vagus nerve will be activated using normal stimulants like food ingestion and vagal activity will be measured using current non-invasive technology. Patients with gastroparesis and healthy controls will be asked to come in fasting, fill out surveys, and complete eating challenges while being connected to an autonomic function testing machine. Exploratory outcomes will also be measured - Participants will be connected to a Peripheral Intravenous Line in order to collect four vials of blood throughout the two hour clinic visit so that hormonal changes can be studied. Also, exploratory non-invasive electrogastrograms will be recorded remotely both during the autonomic function test and for three consecutive days as participants go about their daily lives.
The investigators' goal is to establish a protocol for measuring gastrointestinal evoked vagal activity and correlating activity with digestive function in both healthy people and gastroparesis patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gastroparesis Patients
20 gastroparesis patient ages 20-49
Observational
There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
Healthy Controls
40 healthy controls ages 20-49
Observational
There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational
There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 20-49 years old.
3. Healthy volunteer or established diagnosis of idiopathic gastroparesis as per AGA (American Gastroenterology Association) guidelines.
4. Participant is capable of giving informed consent.
5. Gastroparesis patients must be on stable doses of medications for gastroparesis for preceding 4 weeks prior to enrollment (including cholinergics, anti-cholinergics, dopamine and serotonin receptor agonists/antagonists, motility agents, neuromodulators, herbals).
Exclusion Criteria
2. Surgical-related gastroparesis
3. Extrinsic myopathy or neuropathy causing gastroparesis.
4. Use of narcotic pain medications in the preceding 2 weeks of study enrollment.
5. Patients with enteric feeding tubes or requiring parenteral nutrition.
6. Patients with severe disease flare requiring hospitalization or frequent emergency room visits (last within 3 months or less of enrollment).
7. Untreated significant depression or suicidal thoughts.
8. Pregnant or breast-feeding women.
9. History of gastric pacemaker implantation.
10. Patients with prior gastric surgery, including fundoplication, partial/total gastrectomy, pyloroplasty, or gastric bypass.
11. Patients with implantable electronic devices.
12. Dairy, wheat, or egg allergy/intolerance.
13. Allergy to commercial clinical adhesive for EKG stickers.
14. Non-English speaker and/or hearing impaired (as participants need to follow English verbal commands and cues for the experiment).
20 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Linda Nguyen
Clinical Professor - Medicine/Gastroenterology and Hepatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andres C Gottfried Blackmore, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Linda Nguyen, MD
Role: STUDY_CHAIR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Medical Center
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
44258
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.